profit from every ₹100 of sales.
₹0₹100
Eris Lifesciences
₹1,262.50+0.83% today
-20.7% in 1 year
1-year low ₹1,097.651-year high ₹1,592.45
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹28.27 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Eris Lifesciences sold, what it kept, and what it did with the cash.
Sales went from ₹16.6 billion in 2023 to ₹31.1 billion in 2026, with ₹6.20 billion of profit last year.
SalesProfit
Eris Lifesciences vs. similar companies
Eris Lifesciences grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Eris Lifesciences | 28.3× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Eris Lifesciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 16,618 | 19,913 | 28,793 | 31,149 | |
| 13,047 | 16,037 | 21,653 | 23,193 | |
| 4,222 | 4,954 | 7,017 | 8,406 | |
| 5,479 | 6,987 | 10,356 | 11,107 | |
| 3,822 | 3,921 | 3,518 | 6,195 | |
| 28.07 | 28.79 | 25.81 | 45.26 | |
| 78.5% | 80.5% | 75.2% | 74.5% | |
| 25.4% | 24.9% | 24.4% | 27.0% | |
| 23.0% | 19.7% | 12.2% | 19.9% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 36,673 | 70,405 | 70,332 | 73,655 |
| Cash | 559 | 941 | 1,996 | 547 |
| Total debt | 8,767 | 27,813 | 24,779 | 23,586 |
| Total liabilities | 14,467 | 38,184 | 37,614 | 34,699 |
| 21,960 | 25,862 | 28,544 | 39,027 | |
| 136 | 136 | 136 | 137 | |
| 11.1% | 7.6% | 10.7% | 10.5% | |
| 17.4% | 15.2% | 12.3% | 15.9% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,917 | 4,860 | 10,650 | 5,380 | |
| 8,414 | 1,292 | 1,550 | 2,969 | |
| -5,497 | 3,569 | 9,100 | 2,411 | |
| Dividends paid | 999 | – | 1,001 | – |
| – | – | – | – | |
| 31 | 8 | 91 | 80 |
Valuation
- 28.3×
- –
- 1.64
- 4.9×
- 5.6×
- 72.6×
- 17.8×
- 1.4%
- 3.5%
- –
Profitability
- 74.5%
- 27.0%
- 19.9%
- –
- 10.0%
- 9.5%
- –
- –
- –
- –
Growth
- +23.3%
- +17.3%
- –
- –
- +0.2%
Financial health
- 2.1×
- 0.60
- –
- 4.3×
- 0.74
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 29%of 948
Top 13%of 871
Top 49%of 560
Top 25%of 868
Top 49%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
41No pass
Philip Fisher
68Pass
Peter Lynch
70Pass
Joel Greenblatt
21No pass
Charlie Munger
47No pass
Terry Smith
39No pass
Questions about Eris Lifesciences
Is Eris Lifesciences a good stock to buy?
A solid business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Eris Lifesciences AI analysis
What does Eris Lifesciences do?
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Ahmedabad, India.
Is Eris Lifesciences stock halal?
Yes. Eris Lifesciences passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Eris Lifesciences stock done over the past year?
Down 20.7% over the past twelve months, to ₹1,262.50. It traded between ₹1,097.65 and ₹1,592.45 and is 20.7% below its high.
Who are Eris Lifesciences's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Eris Lifesciences's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.